Nabriva Therapeutics plc of DUBLIN 1, L2, a company, filed a Form D exempt-offering notice with the SEC on 2018-07-27. The offering totals $26.9M, of which $21.3M was reported sold. Industry: Biotechnology.
| Name | Role | Location |
|---|---|---|
| Axel Bolte | Director | Boston, MA |
| Carrie A Bourdow | Director | King of Prussia, PA |
| Colin A Broom | Director | King of Prussia, PA |
| Daniel Burgess | Director | NESS ZIONA, L3 |
| Mark H Corrigan | Director | King of Prussia, PA |
| Charles A Rowland | Director | King of Prussia, PA |
| Theodore Schroeder | Director | King of Prussia, PA |
| George H Talbot | Director | King of Prussia, PA |
| Stephen H Webster | Director | King of Prussia, PA |
| Robert A Crotty | Executive Officer | King of Prussia, PA |
| Steven A Gelone | Executive Officer | King of Prussia, PA |
| Francesco Maria Lavino | Executive Officer | King of Prussia, PA |
| Jennifer Maria Schranz | Executive Officer | King of Prussia, PA |
| Theodore Schroeder | Executive Officer | King of Prussia, PA |
| Gary A Sender | Executive Officer | San Diego, CA |